Thematic review series: Genetics of human lipid diseases - Genetic determinants of hepatic steatosis in man

Journal of Lipid Research

Volumn 52, Issue 4, 2011, Pages 593-617

  Hooper, Amanda J ^a,b,c   Adams, Leon A ^b,d   Burnett, John R ^a,b,c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Alcoholic fatty liver disease; Cirrhosis; Fibrosis; Gene variants; Genetic factors; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Single nucleotide polymorphisms; Susceptibility

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ABC TRANSPORTER; ABC TRANSPORTER C2; ADIPONECTIN; ADIPONECTIN RECEPTOR; ALPHA 1 ANTITRYPSIN; ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN C3; DIACYLGLYCEROL ACYLTRANSFERASE 2; ECTOENZYME NUCLEOTIDE PYROPHOSPHATE PHOSPHODIESTERASE 1; GLUCURONOSYLTRANSFERASE 1A1; GLUTAMATE CYSTEINE LIGASE; HFE PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN RECEPTOR SUBSTRATE 1; MANGANESE SUPEROXIDE DISMUTASE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PHOSPHODIESTERASE; PHOSPHOLIPASE; PROTEIN SERPINA1; STAT3 PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ABETALIPOPROTEINEMIA; CHOLESTEROL ESTER STORAGE DISEASE; CITRULLINEMIA TYPE II; CONGENITAL GENERALIZED LIPODYSTROPHY; DIABETES MELLITUS; DISEASE COURSE; FAMILIAL HYPOBETALIPOPROTEINEMIA; FAMILIAL PARTIAL LIPODYSTROPHY; FAMILIAL PARTIAL LIPODYSTROPHY TYPE 2; FAMILIAL PARTIAL LIPODYSTROPHY TYPE 3; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME ANALYSIS; HERITABILITY; HUMAN; IMMUNOREGULATION; INBORN ERROR OF METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; MUTATIONAL ANALYSIS; NEUTRAL LIPID STORAGE DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; WOLMAN DISEASE; FATTY LIVER; GENETIC PREDISPOSITION; GENETICS; LIVER CIRRHOSIS; MALE; METABOLISM; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER CIRRHOSIS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79953321200     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R008896     Document Type: Review

References (286)

1. Browning, J. D., L. S. Szczepaniak, R. Dobbins, P. Nuremberg, J. D. Horton, J. C. Cohen, S. M. Grundy, and H. H. Hobbs. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 40: 1387-1395.
2. Fan, J. G., J. Zhu, X. J. Li, L. Chen, L. Li, F. Dai, F. Li, and S. Y. Chen. 2005. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. 43: 508-514. (Pubitemid 41111434)
3. Flegal, K. M., M. D. Carroll, C. L. Ogden, and L. R. Curtin. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 303: 235-241.
4. Shaw, J. E., R. A. Sicree, and P. Z. Zimmet. 2010. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87: 4-14.
5. Schwimmer, J. B., R. Deutsch, T. Kahen, J. E. Lavine, C. Stanley, and C. Behling. 2006. Prevalence of fatty liver in children and adolescents. Pediatrics. 118: 1388-1393. (Pubitemid 46393782)
6. Nomura, H., S. Kashiwagi, J. Hayashi, W. Kajiyama, S. Tani, and M. Goto. 1988. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn. J. Med. 27: 142-149.
7. Kleiner, D. E., E. M. Brunt, M. Van Natta, C. Behling, M. J. Contos, O. W. Cummings, L. D. Ferrell, Y. C. Liu, M. S. Torbenson, A. Unalp-Arida, et al. 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41: 1313-1321. (Pubitemid 40770284)
8. Adams, L. A., J. F. Lymp, J. St. Sauver, S. O. Sanderson, K. D. Lindor, A. Feldstein, and P. Angulo. 2005. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 129: 113-121. (Pubitemid 41002048)
9. Malik, S. M., M. E. deVera, P. Fontes, O. Shaikh, and J. Ahmad. 2009. Outcome after liver transplantation for NASH cirrhosis. Am. J. Transplant. 9: 782-793.
10. Angulo, P. 2002. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346: 1221-1231.
11. Sanyal, A. J., C. Banas, C. Sargeant, V. A. Luketic, R. K. Sterling, R. T. Stravitz, M. L. Shiffman, D. Heuman, A. Coterrell, R. A. Fisher, et al. 2006. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 43: 682-689.
12. Marchesini, G., and R. Marzocchi. 2007. Metabolic syndrome and NASH. Clin. Liver Dis. 11: 105-117.
13. Fabbrini, E., F. Magkos, B. S. Mohammed, T. Pietka, N. A. Abumrad, B. W. Patterson, A. Okunade, and S. Klein. 2009. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. USA. 106: 15430-15435.
14. Fabbrini, E., B. S. Mohammed, F. Magkos, K. M. Korenblat, B. W. Patterson, and S. Klein. 2008. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 134: 424-431. (Pubitemid 351173050)
15. Tamura, S., and I. Shimomura. 2005. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest. 115: 1139-1142.
16. Donnelly, K. L., C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115: 1343-1351.
17. Azzout-Marniche, D., D. Becard, C. Guichard, M. Foretz, P. Ferre, and F. Foufelle. 2000. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem. J. 350: 389-393.
18. Browning, J. D., and J. D. Horton. 2004. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114: 147-152.
19. Akkaoui, M., I. Cohen, C. Esnous, V. Lenoir, M. Sournac, J. Girard, and C. Prip-Buus. 2009. Modulation of the hepatic malonyl-CoAcarnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids. Biochem. J. 420: 429-438.
20. McGarry, J. D., G. P. Mannaerts, and D. W. Foster. 1977. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J. Clin. Invest. 60: 265-270.
21. Kohjima, M., N. Higuchi, M. Kato, K. Kotoh, T. Yoshimoto, T. Fujino, M. Yada, R. Yada, N. Harada, M. Enjoji, et al. 2008. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int. J. Mol. Med. 21: 507-511.
22. Pettinelli, P., T. Del Pozo, J. Araya, R. Rodrigo, A. V. Araya, G. Smok, A. Csendes, L. Gutierrez, J. Rojas, O. Korn, et al. 2009. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim. Biophys. Acta. 1792: 1080-1086.
23. H'Ng M. W., and J. W. Kwek. 2010. Imaging appearance of severe subcapsular hepatic steatosis: mimicking hepatic embolic infarcts. Br. J. Radiol. 83: e98-e100.
24. Charlton, M., R. Sreekumar, D. Rasmussen, K. Lindor, and K. S. Nair. 2002. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 35: 898-904.
25. Letteron, P., A. Sutton, A. Mansouri, B. Fromenty, and D. Pessayre. 2003. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 38: 133-140. (Pubitemid 36775804)
26. Day, C. P., and O. F. James. 1998. Steatohepatitis: a tale of two "hits"? Gastroenterology. 114: 842-845.
27. Haque, M., and A. J. Sanyal. 2002. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol. 16: 709-731.
28. Sanyal, A. J., C. Campbell-Sargent, F. Mirshahi, W. B. Rizzo, M. J. Contos, R. K. Sterling, V. A. Luketic, M. L. Shiffman, and J. N. Clore. 2001. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120: 1183-1192.
29. Malhi, H., S. F. Bronk, N. W. Werneburg, and G. J. Gores. 2006. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 281: 12093-12101.
30. Feldstein, A. E., A. Canbay, P. Angulo, M. Taniai, L. J. Burgart, K. D. Lindor, and G. J. Gores. 2003. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 125: 437-443.
31. Feldstein, A. E., N. W. Werneburg, A. Canbay, M. E. Guicciardi, S. F. Bronk, R. Rydzewski, L. J. Burgart, and G. J. Gores. 2004. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 40: 185-194.
32. van der Poorten, D., K. L. Milner, J. Hui, A. Hodge, M. I. Trenell, J. G. Kench, R. London, T. Peduto, D. J. Chisholm, and J. George. 2008. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 48: 449-457.
33. Valenti, L., A. L. Fracanzani, P. Dongiovanni, G. Santorelli, A. Branchi, E. Taioli, G. Fiorelli, and S. Fargion. 2002. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 122: 274-280. (Pubitemid 34116980)
34. Wigg, A. J., I. C. Roberts-Thomson, R. B. Dymock, P. J. McCarthy, R. H. Grose, and A. G. Cummins. 2001. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 48: 206-211.
35. Hui, J. M., A. Hodge, G. C. Farrell, J. G. Kench, A. Kriketos, and J. George. 2004. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 40: 46-54.
36. Tomita, K., Y. Oike, T. Teratani, T. Taguchi, M. Noguchi, T. Suzuki, A. Mizutani, H. Yokoyama, R. Irie, H. Sumimoto, et al. 2008. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology. 48: 458-473.
37. Xu, A., Y. Wang, H. Keshaw, L. Y. Xu, K. S. Lam, and G. J. Cooper. 2003. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112: 91-100.
38. Kaser, S., A. Moschen, A. Cayon, A. Kaser, J. Crespo, F. Pons- Romero, C. F. Ebenbichler, J. R. Patsch, and H. Tilg. 2005. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 54: 117-121. (Pubitemid 40007229)
39. Gastaldelli, A., S. Harrison, R. Belfort-Aguiar, J. Hardies, B. Balas, S. Schenker, and K. Cusi. 2010. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment. Pharmacol. Ther. 32: 769-775.
40. Chung, M. Y., S. F. Yeung, H. J. Park, J. S. Volek, and R. S. Bruno. 2010. Dietary alpha-and gamma-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and infl ammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. J. Nutr. Biochem. 21: 1200-1206.
41. Yang, S., H. Lin, and A. M. Diehl. 2001. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G382-G392.
42. Day, C. P. 2006. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int. 26: 1021-1028. (Pubitemid 44541742)
43. Guerrero, R., G. L. Vega, S. M. Grundy, and J. D. Browning. 2009. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology. 49: 791-801.
44. Browning, J. D., K. S. Kumar, M. H. Saboorian, and D. L. Thiele. 2004. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol. 99: 292-298.
45. Wagenknecht, L. E., A. L. Scherzinger, E. R. Stamm, A. J. Hanley, J. M. Norris, Y. D. Chen, M. Bryer-Ash, S. M. Haffner, and J. I. Rotter. 2009. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring). 17: 1240-1246.
46. Petersen, K. F., S. Dufour, J. Feng, D. Befroy, J. Dziura, C. Dalla Man, C. Cobelli, and G. I. Shulman. 2006. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl. Acad. Sci. USA. 103: 18273-18277.
47. Ibrahim, M. M. 2010. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11: 11-18.
48. Brouwers, M. C., R. M. Cantor, N. Kono, J. L. Yoon, C. J. van der Kallen, M. A. Bilderbeek-Beckers, M. M. van Greevenbroek, A. J. Lusis, and T. W. de Bruin. 2006. Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. J. Lipid Res. 47: 2799-2807. (Pubitemid 44936093)
49. Knopp, R. H., P. Paramsothy, B. M. Retzlaff, B. Fish, C. Walden, A. Dowdy, C. Tsunehara, K. Aikawa, and M. C. Cheung. 2005. Gender differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr. Atheroscler. Rep. 7: 472-479.
50. Schwimmer, J. B., M. A. Celedon, J. E. Lavine, R. Salem, N. Campbell, N. J. Schork, M. Shiehmorteza, T. Yokoo, A. Chavez, M. S. Middleton, et al. 2009. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 136: 1585-1592.
51. Speliotes, E. K. 2009. Genetics of common obesity and nonalcoholic fatty liver disease. Gastroenterology. 136: 1492-1495.
52. Berriot-Varoqueaux, N., L. P. Aggerbeck, M. Samson-Bouma, and J. R. Wetterau. 2000. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu. Rev. Nutr. 20: 663-697.
53. Kane, J. P., and R. J. Havel. 2001. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle, B. Childs, K. Kinzler, and B. Vogelstein, editors. McGraw-Hill, New York. 2717-2752.
54. Hooper, A. J., F. M. van Bockxmeer, and J. R. Burnett. 2005. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit. Rev. Clin. Lab. Sci. 42: 515-545.
55. Avigan, M. I., K. G. Ishak, R. E. Gregg, and J. H. Hoofnagle. 1984. Morphologic features of the liver in abetalipoproteinemia. Hepatology. 4: 1223-1226.
56. Black, D. D., R. V. Hay, P. L. Rohwer-Nutter, H. Ellinas, J. K. Stephens, H. Sherman, B. B. Teng, P. F. Whitington, and N. O. Davidson. 1991. Intestinal and hepatic apolipoprotein B gene expression in abetalipoproteinemia. Gastroenterology. 101: 520-528
57. Braegger, C. P., D. C. Belli, G. Mentha, and B. Steinmann. 1998. Persistence of the intestinal defect in abetalipoproteinaemia after liver transplantation. Eur. J. Pediatr. 157: 576-578.
58. Illingworth, D. R., W. E. Connor, and R. G. Miller. 1980. Abetalipoproteinemia. Report of two cases and review of therapy. Arch. Neurol. 37: 659-662.
59. Partin, J. S., J. C. Partin, W. K. Schubert, and A. J. McAdams. 1974. Liver ultrastructure in abetalipoproteinemia: Evolution of micronodular cirrhosis. Gastroenterology. 67: 107-118.
60. Sharp, D., L. Blinderman, K. A. Combs, B. Kienzle, B. Ricci, K. Wager-Smith, C. M. Gil, C. W. Turck, M. E. Bouma, D. J. Rader, et al. 1993. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 365: 65-69. (Pubitemid 23305570)
61. Shoulders, C. C., D. J. Brett, J. D. Bayliss, T. M. Narcisi, A. Jarmuz, T. T. Grantham, P. R. Leoni, S. Bhattacharya, R. J. Pease, P. M. Cullen, et al. 1993. Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum. Mol. Genet. 2: 2109-2116.
62. Burnett, J. R., and G. F. Watts. 2007. MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises? Expert Opin. Ther. Targets. 11: 181-189.
63. Hussain, M. M., and A. Bakillah. 2008. New approaches to target microsomal triglyceride transfer protein. Curr. Opin. Lipidol. 19: 572-578.
64. Rizzo, M. 2010. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs. 13: 103-111.
65. Samaha, F. F., J. McKenney, L. T. Bloedon, W. J. Sasiela, and D. J. Rader. 2008. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 5: 497-505.
66. Wierzbicki, A. S., T. Hardman, and W. T. Prince. 2009. Future challenges for microsomal transport protein inhibitors. Curr. Vasc. Pharmacol. 7: 277-286.
67. Zeissig, S., S. K. Dougan, D. C. Barral, Y. Junker, Z. Chen, A. Kaser, M. Ho, H. Mandel, A. McIntyre, S. M. Kennedy, et al. 2010. Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. J. Clin. Invest. 120: 2889-2899.
68. Whitfield, A. J., P. H. Barrett, K. Robertson, M. F. Havlat, F. M. van Bockxmeer, and J. R. Burnett. 2005. Liver dysfunction and steatosis in familial hypobetalipoproteinemia. Clin. Chem. 51: 266-269.
69. Ogata, H., K. Akagi, M. Baba, A. Nagamatsu, N. Suzuki, K. Nomiyama, and M. Fujishima. 1997. Fatty liver in a case with heterozygous familial hypobetalipoproteinemia. Am. J. Gastroenterol. 92: 339-342.
70. Schonfeld, G., B. W. Patterson, D. A. Yablonskiy, T. S. Tanoli, M. Averna, N. Elias, P. Yue, and J. Ackerman. 2003. Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J. Lipid Res. 44: 470-478. (Pubitemid 37279694)
71. Tanoli, T., P. Yue, D. Yablonskiy, and G. Schonfeld. 2004. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J. Lipid Res. 45: 941-947. (Pubitemid 38552865)
72. Tarugi, P., A. Lonardo, G. Ballarini, L. Erspamer, E. Tondelli, S. Bertolini, and S. Calandra. 2000. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J. Hepatol. 33: 361-370. (Pubitemid 30663372)
73. Tarugi, P., A. Lonardo, G. Ballarini, A. Grisendi, M. Pulvirenti, A. Bagni, and S. Calandra. 1996. Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. Gastroenterology. 111: 1125-1133. (Pubitemid 26327617)
74. Welty, F. K., C. Lahoz, K. L. Tucker, J. M. Ordovas, P. W. Wilson, and E. J. Schaefer. 1998. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the Framingham Offspring population. Arterioscler. Thromb. Vasc. Biol. 18: 1745-1751.
75. Di Leo, E., L. Magnolo, M. Bertolotti, M. Bourbon, S. Carmo Pereira, M. Pirisi, S. Calandra, and P. Tarugi. 2008. Variable phenotypic expression of homozygous familial hypobetalipoproteinaemia due to novel APOB gene mutations. Clin. Genet. 74: 267-273.
76. Katsuda, S., M. A. Kawashiri, A. Inazu, H. Tada, M. Tsuchida, Y. Kaneko, T. Nozue, A. Nohara, T. Okada, J. Kobayashi, et al. 2009. Apolipoprotein B gene mutations and fatty liver in Japanese hypobetalipoproteinemia. Clin. Chim. Acta. 399: 64-68.
77. Whitfield, A. J., P. H. Barrett, F. M. van Bockxmeer, and J. R. Burnett. 2004. Lipid disorders and mutations in the APOB gene. Clin. Chem. 50: 1725-1732.
78. Burnett, J. R., J. Shan, B. A. Miskie, A. J. Whitfield, J. Yuan, K. Tran, C. J. McKnight, R. A. Hegele, and Z. Yao. 2003. A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. J. Biol. Chem. 278: 13442-13452.
79. Burnett, J. R., S. Zhong, Z. G. Jiang, A. J. Hooper, E. A. Fisher, R. S. McLeod, Y. Zhao, P. H. Barrett, R. A. Hegele, F. M. van Bockxmeer, et al. 2007. Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia. J. Biol. Chem. 282: 24270-24283.
80. Zhong, S., A. L. Magnolo, M. Sundaram, H. Zhou, E. F. Yao, E. Di Leo, P. Loria, S. Wang, M. Bamji-Mirza, L. Wang, et al. 2010. Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B. J. Biol. Chem. 285: 6453-6464.
81. Sankatsing, R. R., S. W. Fouchier, S. de Haan, B. A. Hutten, E. de Groot, J. J. Kastelein, and E. S. Stroes. 2005. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 25: 1979-1984.
82. Elias, N., B. W. Patterson, and G. Schonfeld. 1999. Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 19: 2714-2721.
83. Lin, X., Z. Chen, P. Yue, M. R. Averna, R. E. Ostlund, Jr., M. A. Watson, and G. Schonfeld. 2006. A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G1170-G1176.
84. Lin, X., G. Schonfeld, P. Yue, and Z. Chen. 2002. Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation. Arterioscler. Thromb. Vasc. Biol. 22: 476-482.
85. Lin, X., P. Yue, Y. Xie, N. O. Davidson, N. Sakata, R. E. Ostlund, Jr., Z. Chen, and G. Schonfeld. 2005. Reduced intestinal fat absorptive capacity but enhanced susceptibility to diet-induced fatty liver in mice heterozygous for ApoB38.9 truncation. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G146-G152.
86. Amaro, A., E. Fabbrini, M. Kars, P. Yue, K. Schechtman, G. Schonfeld, and S. Klein. 2010. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology. 139: 149-153.
87. Kobayashi, K., D. S. Sinasac, M. Iijima, A. P. Boright, L. Begum, J. R. Lee, T. Yasuda, S. Ikeda, R. Hirano, H. Terazono, et al. 1999. The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein. Nat. Genet. 22: 159-163.
88. Saheki, T., K. Kobayashi, M. Iijima, M. Horiuchi, L. Begum, M. A. Jalil, M. X. Li, Y. B. Lu, M. Ushikai, A. Tabata, et al. 2004. Adult-onset type II citrullinemia and idiopathic neonatal hepatitis caused by citrin deficiency: involvement of the aspartate glutamate carrier for urea synthesis and maintenance of the urea cycle. Mol. Genet. Metab. 81 ( Suppl 1 ): S20-S26.
89. Tabata, A., J. S. Sheng, M. Ushikai, Y. Z. Song, H. Z. Gao, Y. B. Lu, F. Okumura, M. Iijima, K. Mutoh, S. Kishida, et al. 2008. Identification of 13 novel mutations including a retrotransposal insertion in SLC25A13 gene and frequency of 30 mutations found in patients with citrin deficiency. J. Hum. Genet. 53: 534-545.
90. Saheki, T., K. Kobayashi, M. Iijima, M. Moriyama, M. Yazaki, Y. Takei, and S. Ikeda. 2005. Metabolic derangements in deficiency of citrin, a liver-type mitochondrial aspartate-glutamate carrier. Hepatol. Res. 33: 181-184.
91. Takagi, H., S. Hagiwara, H. Hashizume, D. Kanda, K. Sato, N. Sohara, S. Kakizaki, H. Takahashi, M. Mori, H. Kaneko, et al. 2006. Adult onset type II citrullinemia as a cause of non-alcoholic steatohepatitis. J. Hepatol. 44: 236-239. (Pubitemid 41772540)
92. Komatsu, M., M. Yazaki, N. Tanaka, K. Sano, E. Hashimoto, Y. Takei, Y. Z. Song, E. Tanaka, K. Kiyosawa, T. Saheki, et al. 2008. Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. J. Hepatol. 49: 810-820.
93. Tanaka, N., M. Yazaki, and K. Kobayashi. 2007. A lean man with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 5: A32.
94. Palmieri, L., B. Pardo, F. M. Lasorsa, A. del Arco, K. Kobayashi, M. Iijima, M. J. Runswick, J. E. Walker, T. Saheki, J. Satrustegui, et al. 2001. Citrin and aralar1 are Ca(2+)-stimulated aspartate/ glutamate transporters in mitochondria. EMBO J. 20: 5060-5069.
95. Saheki, T., and K. Kobayashi. 2002. Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). J. Hum. Genet. 47: 333-341. (Pubitemid 34733510)
96. Tazawa, Y., D. Abukawa, O. Sakamoto, I. Nagata, J. Murakami, T. Iizuka, M. Okamoto, A. Kimura, T. Kurosawa, K. Iinuma, et al. 2005. A possible mechanism of neonatal intrahepatic cholestasis caused by citrin deficiency. Hepatol. Res. 31: 168-171.
97. Tazawa, Y., K. Kobayashi, D. Abukawa, I. Nagata, S. Maisawa, R. Sumazaki, T. Iizuka, Y. Hosoda, M. Okamoto, J. Murakami, et al. 2004. Clinical heterogeneity of neonatal intrahepatic cholestasis caused by citrin deficiency: case reports from 16 patients. Mol. Genet. Metab. 83: 213-219.
98. Kimura, A., M. Kage, I. Nagata, S. Mushiake, T. Ohura, Y. Tazawa, S. Maisawa, T. Tomomasa, D. Abukawa, Y. Okano, et al. 2010. Histological findings in the livers of patients with neonatal intrahepatic cholestasis caused by citrin deficiency. Hepatol. Res. 40: 295-303.
99. Tomomasa, T., K. Kobayashi, H. Kaneko, H. Shimura, T. Fukusato, M. Tabata, Y. Inoue, S. Ohwada, M. Kasahara, Y. Morishita, et al. 2001. Possible clinical and histologic manifestations of adult-onset type II citrullinemia in early infancy. J. Pediatr. 138: 741-743. (Pubitemid 32417678)
100. Hegele, R. A., T. R. Joy, S. A. Al-Attar, and B. K. Rutt. 2007. Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism. J. Lipid Res. 48: 1433-1444.
101. Caux, F., E. Dubosclard, O. Lascols, B. Buendia, O. Chazouilleres, A. Cohen, J. C. Courvalin, L. Laroche, J. Capeau, C. Vigouroux, et al. 2003. A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J. Clin. Endocrinol. Metab. 88: 1006-1013.
102. Cao, H., and R. A. Hegele. 2000. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 9: 109-112.
103. Worman, H. J., L. G. Fong, A. Muchir, and S. G. Young. 2009. Laminopathies and the long strange trip from basic cell biology to therapy. J. Clin. Invest. 119: 1825-1836.
104. Ludtke, A., J. Genschel, G. Brabant, J. Bauditz, M. Taupitz, M. Koch, W. Wermke, H. J. Worman, and H. H. Schmidt. 2005. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am. J. Gastroenterol. 100: 2218-2224.
105. Tan, G. D., D. B. Savage, B. A. Fielding, J. Collins, L. Hodson, S. M. Humphreys, S. O'Rahilly, K. Chatterjee, K. N. Frayn, and F. Karpe. 2008. Fatty acid metabolism in patients with PPARgamma mutations. J. Clin. Endocrinol. Metab. 93: 4462-4470.
106. He, W., Y. Barak, A. Hevener, P. Olson, D. Liao, J. Le, M. Nelson, E. Ong, J. M. Olefsky, and R. M. Evans. 2003. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA. 100: 15712-15717.
107. Haque, W. A., F. Vuitch, and A. Garg. 2002. Post-mortem findings in familial partial lipodystrophy, Dunnigan variety. Diabet. Med. 19: 1022-1025.
108. Agarwal, A. K., E. Arioglu, S. De Almeida, N. Akkoc, S. I. Taylor, A. M. Bowcock, R. I. Barnes, and A. Garg. 2002. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet. 31: 21-23.
109. Agarwal, A. K., and A. Garg. 2003. Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways. Trends Endocrinol. Metab. 14: 214-221.
110. Garg, A., and A. K. Agarwal. 2009. Lipodystrophies: disorders of adipose tissue biology. Biochim. Biophys. Acta. 1791: 507-513.
111. Jeninga, E. H., and E. Kalkhoven. 2010. Central players in inherited lipodystrophies. Trends Endocrinol. Metab. 21: 581-588.
112. Gale, S. E., A. Frolov, X. Han, P. E. Bickel, L. Cao, A. Bowcock, J. E. Schaffer, and D. S. Ory. 2006. A regulatory role for 1-acylglycerol- 3-phosphate-O-acyltransferase 2 in adipocyte differentiation. J. Biol. Chem. 281: 11082-11089.
113. Cortes, V. A., D. E. Curtis, S. Sukumaran, X. Shao, V. Parameswara, S. Rashid, A. R. Smith, J. Ren, V. Esser, R. E. Hammer, et al. 2009. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab. 9: 165-176.
114. Van Maldergem, L., J. Magre, T. E. Khallouf, T. Gedde-Dahl, Jr., M. Delepine, O. Trygstad, E. Seemanova, T. Stephenson, C. S. Albott, F. Bonnici, et al. 2002. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J. Med. Genet. 39: 722-733.
115. Magre, J., M. Delepine, E. Khallouf, T. Gedde-Dahl, Jr., L. Van Maldergem, E. Sobel, J. Papp, M. Meier, A. Megarbane, A. Bachy, et al. 2001. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat. Genet. 28: 365-370.
116. Payne, V. A., N. Grimsey, A. Tuthill, S. Virtue, S. L. Gray, E. Dalla Nora, R. K. Semple, S. O'Rahilly, and J. J. Rochford. 2008. The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes. 57: 2055-2060.
117. Chen, W., V. K. Yechoor, B. H. Chang, M. V. Li, K. L. March, and L. Chan. 2009. The human lipodystrophy gene product Berardinelli-Seip congenital lipodystrophy 2/seipin plays a key role in adipocyte differentiation. Endocrinology. 150: 4552-4561.
118. Haemmerle, G., A. Lass, R. Zimmermann, G. Gorkiewicz, C. Meyer, J. Rozman, G. Heldmaier, R. Maier, C. Theussl, S. Eder, et al. 2006. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 312: 734-737.
119. Lass, A., R. Zimmermann, G. Haemmerle, M. Riederer, G. Schoiswohl, M. Schweiger, P. Kienesberger, J. G. Strauss, G. Gorkiewicz, and R. Zechner. 2006. Adipose triglyceride lipasemediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome. Cell Metab. 3: 309-319.
120. Zechner, R., P. C. Kienesberger, G. Haemmerle, R. Zimmermann, and A. Lass. 2009. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. J. Lipid Res. 50: 3-21.
121. Brown, J. M., J. L. Betters, C. Lord, Y. Ma, X. Han, K. Yang, H. M. Alger, J. Melchior, J. Sawyer, R. Shah, et al. 2010. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J. Lipid Res. 51: 3306-3315.
122. Schweiger, M., A. Lass, R. Zimmermann, T. O. Eichmann, and R. Zechner. 2009. Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. Am. J. Physiol. Endocrinol. Metab. 297: E289-E296.
123. Akiyama, M., K. Sakai, M. Ogawa, J. R. McMillan, D. Sawamura, and H. Shimizu. 2007. Novel duplication mutation in the patatin domain of adipose triglyceride lipase (PNPLA2) in neutral lipid storage disease with severe myopathy. Muscle Nerve. 36: 856-859. (Pubitemid 350246936)
124. Schweiger, M., G. Schoiswohl, A. Lass, F. P. Radner, G. Haemmerle, R. Malli, W. Graier, I. Cornaciu, M. Oberer, R. Salvayre, et al. 2008. The C-terminal region of human adipose triglyceride lipase affects enzyme activity and lipid droplet binding. J. Biol. Chem. 283: 17211-17220.
125. Du, H., T. L. Cameron, S. J. Garger, G. P. Pogue, L. A. Hamm, E. White, K. M. Hanley, and G. A. Grabowski. 2008. Wolman disease/ cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. J. Lipid Res. 49: 1646-1657.
126. Aslanidis, C., S. Ries, P. Fehringer, C. Buchler, H. Klima, and G. Schmitz. 1996. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics. 33: 85-93. (Pubitemid 26119398)
127. Meikle, P. J., J. J. Hopwood, A. E. Clague, and W. F. Carey. 1999. Prevalence of lysosomal storage disorders. JAMA. 281: 249-254.
128. Decarlis, S., C. Agostoni, F. Ferrante, S. Scarlino, E. Riva, and M. Giovannini. 2009. Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease. J. Inherit. Metab. Dis.
129. Hooper, A. J., H. A. Tran, M. R. Formby, and J. R. Burnett. 2008. A novel missense LIPA gene mutation, N98S, in a patient with cholesteryl ester storage disease. Clin. Chim. Acta. 398: 152-154.
130. Todoroki, T., K. Matsumoto, K. Watanabe, Y. Tashiro, M. Shimizu, T. Okuyama, and K. Imai. 2000. Accumulated lipids, aberrant fatty acid composition and defective cholesterol ester hydrolase activity in cholesterol ester storage disease. Ann. Clin. Biochem. 37: 187-193.
131. Klima, H., K. Ullrich, C. Aslanidis, P. Fehringer, K. J. Lackner, and G. Schmitz. 1993. A splice junction mutation causes deletion of a 72-base exon from the mRNA for lysosomal acid lipase in a patient with cholesteryl ester storage disease. J. Clin. Invest. 92: 2713-2718.
132. Muntoni, S., H. Wiebusch, M. Jansen-Rust, S. Rust, U. Seedorf, H. Schulte, K. Berger, H. Funke, and G. Assmann. 2007. Prevalence of cholesteryl ester storage disease. Arterioscler. Thromb. Vasc. Biol. 27: 1866-1868.
133. Pagani, F., R. Pariyarath, R. Garcia, C. Stuani, A. B. Burlina, G. Ruotolo, M. Rabusin, and F. E. Baralle. 1998. New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease. J. Lipid Res. 39: 1382-1388.
134. Saudubray, J. M., D. Martin, P. de Lonlay, G. Touati, F. Poggi- Travert, D. Bonnet, P. Jouvet, M. Boutron, A. Slama, C. Vianey-Saban, et al. 1999. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J. Inherit. Metab. Dis. 22: 488-502.
135. Zhang, D., Z. X. Liu, C. S. Choi, L. Tian, R. Kibbey, J. Dong, G. W. Cline, P. A. Wood, and G. I. Shulman. 2007. Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc. Natl. Acad. Sci. USA. 104: 17075-17080.
136. Tucci, S., S. Primassin, F. Ter Veld, and U. Spiekerkoetter. 2010. Medium-chain triglycerides impair lipid metabolism and induce hepatic steatosis in very long-chain acyl-CoA dehydrogenase (VLCAD)-deficient mice. Mol. Genet. Metab. 101: 40-47.
137. Ibdah, J. A., M. J. Bennett, P. Rinaldo, Y. Zhao, B. Gibson, H. F. Sims, and A. W. Strauss. 1999. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N. Engl. J. Med. 340: 1723-1731.
138. Lee, N. M., and C. W. Brady. 2009. Liver disease in pregnancy. World J. Gastroenterol. 15: 897-906.
139. Mackillop, L., and C. Williamson. 2010. Liver disease in pregnancy. Postgrad. Med. J. 86: 160-164.
140. Ibdah, J. A. 2006. Acute fatty liver of pregnancy: an update on pathogenesis and clinical implications. World J. Gastroenterol. 12: 7397-7404.
141. Gillingham, M. B., J. Q. Purnell, J. Jordan, D. Stadler, A. M. Haqq, and C. O. Harding. 2007. Effects of higher dietary protein intake on energy balance and metabolic control in children with longchain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol. Genet. Metab. 90: 64-69.
142. Semple, R. K., A. Sleigh, P. R. Murgatroyd, C. A. Adams, L. Bluck, S. Jackson, A. Vottero, D. Kanabar, V. Charlton-Menys, P. Durrington, et al. 2009.
143. George, S., J. J. Rochford, C. Wolfrum, S. L. Gray, S. Schinner, J. C. Wilson, M. A. Soos, P. R. Murgatroyd, R. M. Williams, C. L. Acerini, et al. 2004. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 304: 1325-1328. (Pubitemid 38697429)
144. Romeo, S., J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, L. A. Pennacchio, E. Boerwinkle, J. C. Cohen, and H. H. Hobbs. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40: 1461-1465.
145. Baulande, S., F. Lasnier, M. Lucas, and J. Pairault. 2001. Adiponutrin, a transmembrane protein corresponding to a novel dietary-and obesity-linked mRNA specifically expressed in the adipose lineage. J. Biol. Chem. 276: 33336-33344.
146. Wilson, P. A., S. D. Gardner, N. M. Lambie, S. A. Commans, and D. J. Crowther. 2006. Characterization of the human patatin-like phospholipase family. J. Lipid Res. 47: 1940-1949.
147. Romeo, S., I. Huang-Doran, M. G. Baroni, and A. Kotronen. 2010. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr. Opin. Lipidol. 21: 247-252.
148. Huang, Y., S. He, J. Z. Li, Y. K. Seo, T. F. Osborne, J. C. Cohen, and H. H. Hobbs. 2010. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc. Natl. Acad. Sci. USA. 107: 7892-7897.
149. Chen, W., B. Chang, L. Li, and L. Chan. 2010. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology. 52: 1134-1142.
150. Monetti, M., M. C. Levin, M. J. Watt, M. P. Sajan, S. Marmor, B. K. Hubbard, R. D. Stevens, J. R. Bain, C. B. Newgard, R. V. Farese, Sr., et al. 2007. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 6: 69-78. (Pubitemid 46995777)
151. Kotronen, A., L. E. Johansson, L. M. Johansson, C. Roos, J. Westerbacka, A. Hamsten, R. Bergholm, P. Arkkila, J. Arola, T. Kiviluoto, et al. 2009. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 52: 1056-1060.
152. Kantartzis, K., A. Peter, F. Machicao, J. Machann, S. Wagner, I. Konigsrainer, A. Konigsrainer, F. Schick, A. Fritsche, H. U. Haring, et al. 2009. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 58: 2616-2623.
153. Santoro, N., R. Kursawe, E. D'Adamo, D. J. Dykas, C. K. Zhang, A. E. Bale, A. M. Cali, D. Narayan, M. M. Shaw, B. Pierpont, et al. 2010. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology. 52: 1281-1290.
154. Petit, J. M., B. Guiu, D. Masson, L. Duvillard, V. Jooste, P. Buffier, B. Terriat, B. Bouillet, M. C. Brindisi, et al. 2010. Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 95: E430-E436.
155. Kollerits, B., S. Coassin, S. Kiechl, S. C. Hunt, B. Paulweber, J. Willeit, A. Brandstatter, T. D. Adams, and F. Kronenberg. 2010. A common variant in the adiponutrin gene influences liver enzyme levels. J. Med. Genet. 47: 116-119.
156. Kollerits, B., S. Coassin, N. D. Beckmann, A. Teumer, S. Kiechl, A. Doring, M. Kavousi, S. C. Hunt, C. Lamina, B. Paulweber, et al. 2009. Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Hum. Mol. Genet. 18: 4669-4676.
157. Johansson, L. E., J. Hoffstedt, H. Parikh, E. Carlsson, M. Wabitsch, A. G. Bondeson, J. Hedenbro, H. Tornqvist, L. Groop, and M. Ridderstrale. 2006. Variation in the adiponutrin gene influences its expression and associates with obesity. Diabetes. 55: 826-833. (Pubitemid 43343243)
158. Sookoian, S., G. O. Castano, A. L. Burgueno, T. F. Gianotti, M. S. Rosselli, and C. J. Pirola. 2009. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J. Lipid Res. 50: 2111-2116.
159. Rotman, Y., C. Koh, J. M. Zmuda, D. E. Kleiner, and T. J. Liang. 2010. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 52: 894-903.
160. Valenti, L., A. Alisi, E. Galmozzi, A. Bartuli, B. Del Menico, A. Alterio, P. Dongiovanni, S. Fargion, and V. Nobili. 2010. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology. 52: 1274-1280.
161. Tian, C., R. P. Stokowski, D. Kershenobich, D. G. Ballinger, and D. A. Hinds. 2010. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 42: 21-23.
162. Valenti, L., A. Al-Serri, A. K. Daly, E. Galmozzi, R. Rametta, P. Dongiovanni, V. Nobili, E. Mozzi, G. Roviaro, E. Vanni, et al. 2010. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 51: 1209-1217.
163. Romeo, S., F. Sentinelli, S. Dash, G. S. Yeo, D. B. Savage, F. Leonetti, D. Capoccia, M. Incani, C. Maglio, et al. 2010. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int. J. Obes. (Lond.). 34: 190-194.
164. Jenkins, C. M., D. J. Mancuso, W. Yan, H. F. Sims, B. Gibson, and R. W. Gross. 2004. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J. Biol. Chem. 279: 48968-48975.
165. Kershaw, E. E., J. K. Hamm, L. A. Verhagen, O. Peroni, M. Katic, and J. S. Flier. 2006. Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes. 55: 148-157.
166. Lake, A. C., Y. Sun, J. L. Li, J. E. Kim, J. W. Johnson, D. Li, T. Revett, H. H. Shih, W. Liu, J. E. Paulsen, et al. 2005. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J. Lipid Res. 46: 2477-2487. (Pubitemid 41532536)
167. He, S., C. McPhaul, J. Z. Li, R. Garuti, L. Kinch, N. V. Grishin, J. C. Cohen, and H. H. Hobbs. 2010. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285: 6706-6715.
168. Moldes, M., G. Beauregard, M. Faraj, N. Peretti, P. H. Ducluzeau, M. Laville, R. Rabasa-Lhoret, H. Vidal, and K. Clement. 2006. Adiponutrin gene is regulated by insulin and glucose in human adipose tissue. Eur. J. Endocrinol. 155: 461-468.
169. Liu, Y. M., M. Moldes, J. P. Bastard, E. Bruckert, N. Viguerie, B. Hainque, A. Basdevant, D. Langin, J. Pairault, and K. Clement. 2004. Adiponutrin: a new gene regulated by energy balance in human adipose tissue. J. Clin. Endocrinol. Metab. 89: 2684-2689.
170. Johansson, L. E., U. Lindblad, C. A. Larsson, L. Rastam, and M. Ridderstrale. 2008. Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity. Eur. J. Endocrinol. 159: 577-583.
171. Yuan, X., D. Waterworth, J. R. Perry, N. Lim, K. Song, J. C. Chambers, W. Zhang, P. Vollenweider, H. Stirnadel, T. Johnson, et al. 2008. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am. J. Hum. Genet. 83: 520-528.
172. Petersen, K. F., S. Dufour, A. Hariri, C. Nelson-Williams, J. N. Foo, X. M. Zhang, J. Dziura, R. P. Lifton, and G. I. Shulman. 2010. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362: 1082-1089.
173. Hussain, M. M., J. Shi, and P. Dreizen. 2003. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res. 44: 22-32. (Pubitemid 36114766)
174. Fujita, K., Y. Nozaki, K. Wada, M. Yoneda, Y. Fujimoto, M. Fujitake, H. Endo, H. Takahashi, M. Inamori, N. Kobayashi, et al. 2009. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 50: 772-780.
175. Perlemuter, G., A. Sabile, P. Letteron, G. Vona, A. Topilco, Y. Chretien, K. Koike, D. Pessayre, J. Chapman, G. Barba, et al. 2002. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 16: 185-194. (Pubitemid 34113012)
176. Petit, J. M., M. Benichou, L. Duvillard, V. Jooste, J. B. Bour, A. Minello, B. Verges, J. M. Brun, P. Gambert, and P. Hillon. 2003. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am. J. Gastroenterol. 98: 1150-1154.
177. Bernard, S., S. Touzet, I. Personne, V. Lapras, P. J. Bondon, F. Berthezene, and P. Moulin. 2000. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia. 43: 995-999. (Pubitemid 30655718)
178. Namikawa, C., Z. Shu-Ping, J. R. Vyselaar, Y. Nozaki, Y. Nemoto, M. Ono, N. Akisawa, T. Saibara, M. Hiroi, H. Enzan, et al. 2004. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 40: 781-786. (Pubitemid 38507358)
179. Mirandola, S., D. Bowman, M. M. Hussain, and A. Alberti. 2010. Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). Nutr. Metab. (Lond.). 7: 13.
180. Zampino, R., D. Ingrosso, E. Durante-Mangoni, R. Capasso, M. F. Tripodi, L. Restivo, V. Zappia, G. Ruggiero, and L. E. Adinolfi. 2008. Microsomal triglyceride transfer protein (MTP)-493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J. Viral Hepat. 15: 740-746.
181. Mirandola, S., C. H. Osterreicher, M. Marcolongo, C. Datz, E. Aigner, A. Schlabrakowski, S. Realdon, M. Gerotto, A. Alberti, and F. Stickel. 2009. Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C. Liver Int. 29: 557-565.
182. Musso, G., R. Gambino, and M. Cassader. 2010. Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. J. Nutr. Biochem. 21: 834-840.
183. Gambino, R., M. Cassader, G. Pagano, M. Durazzo, and G. Musso. 2007. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology. 45: 1097-1107.
184. Yu, Y. H., and H. N. Ginsberg. 2004. The role of acyl- CoA: diacylglycerol acyltransferase (DGAT) in energy metabolism. Ann. Med. 36: 252-261.
185. Millar, J. S., S. J. Stone, U. J. Tietge, B. Tow, J. T. Billheimer, J. S. Wong, R. L. Hamilton, R. V. Farese, Jr., and D. J. Rader. 2006. Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. J. Lipid Res. 47: 2297-2305.
186. Yu, X. X., S. F. Murray, S. K. Pandey, S. L. Booten, D. Bao, X. Z. Song, S. Kelly, S. Chen, R. McKay, B. P. Monia, et al. 2005. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology. 42: 362-371.
187. Kantartzis, K., F. Machicao, J. Machann, F. Schick, A. Fritsche, H. U. Haring, and N. Stefan. 2009. The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clin. Sci. (Lond.). 116: 531-537.
188. Friedel, S., K. Reichwald, A. Scherag, H. Brumm, A. K. Wermter, H. R. Fries, K. Koberwitz, M. Wabitsch, T. Meitinger, M. Platzer, et al. 2007. Mutation screen and association studies in the diacylglycerol O-acyltransferase homolog 2 gene (DGAT2), a positional candidate gene for early onset obesity on chromosome 11q13. BMC Genet. 8: 17.
189. Reo, N. V., M. Adinehzadeh, and B. D. Foy. 2002. Kinetic analyses of liver phosphatidylcholine and phosphatidylethanolamine biosynthesis using (13)C NMR spectroscopy. Biochim. Biophys. Acta. 1580: 171-188.
190. Vance, D. E., C. J. Walkey, and Z. Cui. 1997. Phosphatidylethanolamine N-methyltransferase from liver. Biochim. Biophys. Acta. 1348: 142-150.
191. Yao, Z. M., and D. E. Vance. 1988. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J. Biol. Chem. 263: 2998-3004.
192. Buchman, A. L., M. D. Dubin, A. A. Moukarzel, D. J. Jenden, M. Roch, K. M. Rice, J. Gornbein, and M. E. Ament. 1995. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology. 22: 1399-1403.
193. Song, J., K. A. da Costa, L. M. Fischer, M. Kohlmeier, L. Kwock, S. Wang, and S. H. Zeisel. 2005. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 19: 1266-1271.
194. Romeo, S., J. C. Cohen, and H. H. Hobbs. 2006. No association between polymorphism in PEMT (V175M) and hepatic triglyceride content in the Dallas Heart Study. FASEB J. 20: 2180 ; author reply 2181-2182.
195. Dong, H., J. Wang, C. Li, A. Hirose, Y. Nozaki, M. Takahashi, M. Ono, N. Akisawa, S. Iwasaki, T. Saibara, et al. 2007. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 46: 915-920. (Pubitemid 46529040)
196. Jun, D. W., J. H. Han, E. C. Jang, S. H. Kim, Y. J. Jo, Y. S. Park, and J. D. Chae. 2009. Polymorphisms of microsomal triglyceride transfer protein gene and phosphatidylethanolamine N-methyltransferase gene in alcoholic and nonalcoholic fatty liver disease in Koreans. Eur. J. Gastroenterol. Hepatol. 21: 667-672.
197. Zeisel, S. H., and J. K. Blusztajn. 1994. Choline and human nutrition. Annu. Rev. Nutr. 14: 269-296.
198. Polyzos, S. A., J. Kountouras, C. Zavos, and E. Tsiaousi. 2010. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes. Metab. 12: 365-383.
199. Musso, G., R. Gambino, F. De Michieli, M. Durazzo, G. Pagano, and M. Cassader. 2008. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology. 47: 1167-1177. (Pubitemid 351547903)
200. Tokushige, K., E. Hashimoto, H. Noto, S. Yatsuji, M. Taniai, N. Torii, and K. Shiratori. 2009. Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. J. Gastroenterol. 44: 976-982.
201. Jang, Y., J. S. Chae, S. J. Koh, Y. J. Hyun, J. Y. Kim, Y. J. Jeong, S. Park, C. M. Ahn, and J. H. Lee. 2008. The influence of the adiponectin gene on adiponectin concentrations and parameters of metabolic syndrome in non-diabetic Korean women. Clin. Chim. Acta. 391: 85-90.
202. Jang, Y., J. H. Lee, J. S. Chae, O. Y. Kim, S. J. Koh, J. Y. Kim, H. Cho, J. E. Lee, and J. M. Ordovas. 2005. Association of the 276G → T polymorphism of the adiponectin gene with cardiovascular disease risk factors in nondiabetic Koreans. Am. J. Clin. Nutr. 82: 760-767.
203. Xita, N., I. Georgiou, A. Chatzikyriakidou, M. Vounatsou, G. P. Papassotiriou, I. Papassotiriou, and A. Tsatsoulis. 2005. Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin. Chem. 51: 416-423.
204. Wong, V. W., G. L. Wong, S. W. Tsang, A. Y. Hui, A. W. Chan, P. C. Choi, W. Y. So, A. M. Tse, F. K. Chan, J. J. Sung, et al. 2008. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J. Gastroenterol. Hepatol. 23: 914-921.
205. Wang, Z. L., B. Xia, U. Shrestha, L. Jiang, C. W. Ma, Q. Chen, H. Chen, and Z. G. Hu. 2008. Correlation between adiponectin polymorphisms and non-alcoholic fatty liver disease with or without metabolic syndrome in Chinese population. J. Endocrinol. Invest. 31: 1086-1091.
206. Kotronen, A., H. Yki-Jarvinen, A. Aminoff, R. Bergholm, K. H. Pietilainen, J. Westerbacka, P. J. Talmud, S. E. Humphries, A. Hamsten, B. Isomaa, et al. 2009. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur. J. Endocrinol. 160: 593-602.
207. Stefan, N., F. Machicao, H. Staiger, J. Machann, F. Schick, O. Tschritter, C. Spieth, C. Weigert, A. Fritsche, M. Stumvoll, et al. 2005. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia. 48: 2282-2291.
208. Dongiovanni, P., L. Valenti, R. Rametta, A. K. Daly, V. Nobili, E. Mozzi, J. B. Leathart, A. Pietrobattista, A. D. Burt, M. Maggioni, et al. 2010. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut. 59: 267-273.
209. Jellema, A., M. P. Zeegers, E. J. Feskens, P. C. Dagnelie, and R. P. Mensink. 2003. Gly972Arg variant in the insulin receptor substrate- 1 gene and association with type 2 diabetes: a meta-analysis of 27 studies. Diabetologia. 46: 990-995.
210. Prudente, S., and V. Trischitta. 2006. Editorial: The pleiotropic effect of the ENPP1 (PC-1) gene on insulin resistance, obesity, and type 2 diabetes. J. Clin. Endocrinol. Metab. 91: 4767-4768.
211. Finck, B. N., and D. P. Kelly. 2006. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 116: 615-622.
212. Lin, J., C. Handschin, and B. M. Spiegelman. 2005. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1: 361-370.
213. Alaynick, W. A. 2008. Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion. 8: 329-337.
214. Herzig, S., F. Long, U. S. Jhala, S. Hedrick, R. Quinn, A. Bauer, D. Rudolph, G. Schutz, C. Yoon, P. Puigserver, et al. 2001. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 413: 179-183. (Pubitemid 32867880)
215. Puigserver, P., J. Rhee, J. Donovan, C. J. Walkey, J. C. Yoon, F. Oriente, Y. Kitamura, J. Altomonte, H. Dong, D. Accili, et al. 2003. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 423: 550-555. (Pubitemid 36648580)
216. Estall, J. L., M. Kahn, M. P. Cooper, F. M. Fisher, M. K. Wu, D. Laznik, L. Qu, D. E. Cohen, G. I. Shulman, and B. M. Spiegelman. 2009. Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes. 58: 1499-1508.
217. Leone, T. C., J. J. Lehman, B. N. Finck, P. J. Schaeffer, A. R. Wende, S. Boudina, M. Courtois, D. F. Wozniak, N. Sambandam, C. Bernal-Mizrachi, et al. 2005. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3: e101.
218. Yoon, J. C., P. Puigserver, G. Chen, J. Donovan, Z. Wu, J. Rhee, G. Adelmant, J. Stafford, C. R. Kahn, D. K. Granner, et al. 2001. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 413: 131-138. (Pubitemid 32867868)
219. Rao, M. S., and J. K. Reddy. 2004. PPARalpha in the pathogenesis of fatty liver disease. Hepatology. 40: 783-786.
220. Belfort, R., S. A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas, A. Gastaldelli, F. Tio, J. Pulcini, et al. 2006. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355: 2297-2307.
221. Yoneda, M., K. Hotta, Y. Nozaki, H. Endo, T. Uchiyama, H. Mawatari, H. Iida, S. Kato, K. Hosono, K. Fujita, et al. 2008. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 8: 27.
222. Hui, Y., L. Yu-Yuan, N. Yu-Qiang, S. Wei-Hong, D. Yan-Lei, L. Xiao-Bo, and Z. Yong-Jian. 2008. Effect of peroxisome proliferator- activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int. 28: 385-392. (Pubitemid 351279587)
223. Esterbauer, H., H. Oberkofler, V. Linnemayr, B. Iglseder, M. Hedegger, P. Wolfsgruber, B. Paulweber, G. Fastner, F. Krempler, and W. Patsch. 2002. Peroxisome proliferator-activated receptorgamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes. 51: 1281-1286. (Pubitemid 34438380)
224. Hara, K., K. Tobe, T. Okada, H. Kadowaki, Y. Akanuma, C. Ito, S. Kimura, and T. Kadowaki. 2002. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to type II diabetes. Diabetologia. 45: 740-743. (Pubitemid 34810700)
225. Oberkofler, H., B. Holzl, H. Esterbauer, M. Xie, B. Iglseder, F. Krempler, B. Paulweber, and W. Patsch. 2003. Peroxisome proliferator- activated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men. Hypertension. 41: 368-372. (Pubitemid 36204916)
226. Oberkofler, H., V. Linnemayr, R. Weitgasser, K. Klein, M. Xie, B. Iglseder, F. Krempler, B. Paulweber, and W. Patsch. 2004. Complex haplotypes of the PGC-1alpha gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes. 53: 1385-1393. (Pubitemid 38569027)
227. Pihlajamaki, J., M. Kinnunen, E. Ruotsalainen, U. Salmenniemi, I. Vauhkonen, T. Kuulasmaa, S. Kainulainen, and M. Laakso. 2005. Haplotypes of PPARGC1A are associated with glucose tolerance, body mass index and insulin sensitivity in offspring of patients with type 2 diabetes. Diabetologia. 48: 1331-1334. (Pubitemid 41186098)
228. Ridderstrale, M., L. E. Johansson, L. Rastam, and U. Lindblad. 2006. Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men. Diabetologia. 49: 496-500. (Pubitemid 43277872)
229. Barroso, I., J. Luan, M. S. Sandhu, P. W. Franks, V. Crowley, A. J. Schafer, S. O'Rahilly, and N. J. Wareham. 2006. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia. 49: 501-505.
230. Ling, C., P. Poulsen, E. Carlsson, M. Ridderstrale, P. Almgren, J. Wojtaszewski, H. Beck-Nielsen, L. Groop, and A. Vaag. 2004. Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J. Clin. Invest. 114: 1518-1526.
231. Franks, P. W., U. Ekelund, S. Brage, J. Luan, A. J. Schafer, S. O'Rahilly, I. Barroso, and N. J. Wareham. 2007. PPARGC1A coding variation may initiate impaired NEFA clearance during glucose challenge. Diabetologia. 50: 569-573.
232. Chen, S., Y. Li, S. Li, and C. Yu. 2008. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J. Gastroenterol. Hepatol. 23: 1415-1418.
233. Cauchi, S., Y. El Achhab, H. Choquet, C. Dina, F. Krempler, R. Weitgasser, C. Nejjari, W. Patsch, M. Chikri, D. Meyre, et al. 2007. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J. Mol. Med. 85: 777-782.
234. Cauchi, S., D. Meyre, C. Dina, H. Choquet, C. Samson, S. Gallina, B. Balkau, G. Charpentier, F. Pattou, V. Stetsyuk, et al. 2006. Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes. 55: 2903-2908. (Pubitemid 44923694)
235. Grant, S. F., G. Thorleifsson, I. Reynisdottir, R. Benediktsson, A. Manolescu, J. Sainz, A. Helgason, H. Stefansson, V. Emilsson, A. Helgadottir, et al. 2006. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38: 320-323.
236. Huertas-Vazquez, A., C. Plaisier, D. Weissglas-Volkov, J. Sinsheimer, S. Canizales-Quinteros, I. Cruz-Bautista, E. Nikkola, M. Herrera-Hernandez, A. Davila-Cervantes, T. Tusie-Luna, et al. 2008. TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. Diabetologia. 51: 62-69. (Pubitemid 50000014)
237. Musso, G., R. Gambino, G. Pacini, G. Pagano, M. Durazzo, and M. Cassader. 2009. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology. 49: 426-435.
238. Fromenty, B., M. A. Robin, A. Igoudjil, A. Mansouri, and D. Pessayre. 2004. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 30: 121-138. (Pubitemid 38715168)
239. Seki, S., T. Kitada, T. Yamada, H. Sakaguchi, K. Nakatani, and K. Wakasa. 2002. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37: 56-62.
240. Gao, D., S. Nong, X. Huang, Y. Lu, H. Zhao, Y. Lin, Y. Man, S. Wang, J. Yang, and J. Li. 2010. The effects of palmitate on hepatic insulin resistance are mediated by NADPH Oxidase 3-derived reactive oxygen species through JNK and p38MAPK pathways. J. Biol. Chem. 285: 29965-29973.
241. JeBailey, L., O. Wanono, W. Niu, J. Roessler, A. Rudich, and A. Klip. 2007. Ceramide-and oxidant-induced insulin resistance involve loss of insulin-dependent Rac-activation and actin remodeling in muscle cells. Diabetes. 56: 394-403.
242. Malaguarnera, L., R. Madeddu, E. Palio, N. Arena, and M. Malaguarnera. 2005. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J. Hepatol. 42: 585-591. (Pubitemid 40342940)
243. Chen, Y., Y. Yang, M. L. Miller, D. Shen, H. G. Shertzer, K. F. Stringer, B. Wang, S. N. Schneider, D. W. Nebert, and T. P. Dalton. 2007. Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure. Hepatology. 45: 1118-1128.
244. Oliveira, C. P., J. T. Stefano, A. M. Cavaleiro, M. A. Fortes, S. M. Vieira, V. M. Lima, T. E. Santos, V. N. Santos, A. L. de Azevedo Salgado, E. R. Parise, et al. 2010. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 25: 357-361.
245. Koide, S., K. Kugiyama, S. Sugiyama, S. Nakamura, H. Fukushima, O. Honda, M. Yoshimura, and H. Ogawa. 2003. Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with coronary vasomotor dysfunction and myocardial infarction. J. Am. Coll. Cardiol. 41: 539-545.
246. Yoneda, M., K. Hotta, Y. Nozaki, H. Endo, W. Tomeno, S. Watanabe, K. Hosono, H. Mawatari, H. Iida, K. Fujita, et al. 2009. Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Hepatol. Res. 39: 963-971.
247. Dickhout, J. G., G. S. Hossain, L. M. Pozza, J. Zhou, S. Lhotak, and R. C. Austin. 2005. Peroxynitrite causes endoplasmic reticulum stress and apoptosis in human vascular endothelium: implications in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 25: 2623-2629.
248. Stewart, S. F., J. B. Leathart, Y. Chen, A. K. Daly, R. Rolla, D. Vay, E. Mottaran, M. Vidali, E. Albano, and C. P. Day. 2002. Valinealanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology. 36: 1355-1360.
249. Moh, A., Y. Iwamoto, G. X. Chai, S. S. Zhang, A. Kano, D. D. Yang, W. Zhang, J. Wang, J. J. Jacoby, B. Gao, et al. 2007. Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery. Lab. Invest. 87: 1018-1028.
250. Inoue, H., W. Ogawa, M. Ozaki, S. Haga, M. Matsumoto, K. Furukawa, N. Hashimoto, Y. Kido, T. Mori, H. Sakaue, et al. 2004. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 10: 168-174.
251. Hong, F., S. Radaeva, H. N. Pan, Z. Tian, R. Veech, and B. Gao. 2004. Interleukin 6 alleviates hepatic steatosis and ischemia/ reperfusion injury in mice with fatty liver disease. Hepatology. 40: 933-941. (Pubitemid 39288127)
252. Sookoian, S., G. Castano, T. F. Gianotti, C. Gemma, M. S. Rosselli, and C. J. Pirola. 2008. Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease. Cytokine. 44: 201-206.
253. Crespo, J., A. Cayon, P. Fernandez-Gil, M. Hernandez-Guerra, M. Mayorga, A. Dominguez-Diez, J. C. Fernandez-Escalante, and F. Pons-Romero. 2001. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 34: 1158-1163. (Pubitemid 33096588)
254. Tokushige, K., M. Takakura, N. Tsuchiya-Matsushita, M. Taniai, E. Hashimoto, and K. Shiratori. 2007. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 46: 1104-1110. (Pubitemid 46669735)
255. Adinolfi, L. E., D. Ingrosso, G. Cesaro, A. Cimmino, M. D'Anto, R. Capasso, V. Zappia, and G. Ruggiero. 2005. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology. 41: 995-1003. (Pubitemid 40593907)
256. Werstuck, G. H., S. R. Lentz, S. Dayal, G. S. Hossain, S. K. Sood, Y. Y. Shi, J. Zhou, N. Maeda, S. K. Krisans, M. R. Malinow, et al. 2001. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Invest. 107: 1263-1273.
257. George, D. K., S. Goldwurm, G. A. MacDonald, L. L. Cowley, N. I. Walker, P. J. Ward, E. C. Jazwinska, and L. W. Powell. 1998. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 114: 311-318.
258. Bonkovsky, H. L., Q. Jawaid, K. Tortorelli, P. LeClair, J. Cobb, R. W. Lambrecht, and B. F. Banner. 1999. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J. Hepatol. 31: 421-429.
259. Chitturi, S., M. Weltman, G. C. Farrell, D. McDonald, J. Kench, C. Liddle, D. Samarasinghe, R. Lin, S. Abeygunasekera, and J. George. 2002. HFE mutations, hepatic iron, and fibrosis: ethnicspecifi c association of NASH with C282Y but not with fibrotic severity. Hepatology. 36: 142-149. (Pubitemid 34700771)
260. Valenti, L., P. Dongiovanni, A. L. Fracanzani, G. Santorelli, E. Fatta, C. Bertelli, E. Taioli, G. Fiorelli, and S. Fargion. 2003. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig. Liver Dis. 35: 172-178.
261. Loria, P., A. Lonardo, and N. Carulli. 2004. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 39: 1748; author reply 1749.
262. Neri, S., D. Pulvirenti, S. Signorelli, L. Ignaccolo, A. Tsami, B. Mauceri, M. Misseri, D. Interlandi, N. Cutuli, and P. Castellino. 2008. The HFE gene heterozygosis H63D: a cofactor for liver damage in patients with steatohepatitis? Epidemiological and clinical considerations. Intern. Med. J. 38: 254-258.
263. Valenti, L., A. L. Fracanzani, E. Bugianesi, P. Dongiovanni, E. Galmozzi, E. Vanni, E. Canavesi, E. Lattuada, G. Roviaro, G. Marchesini, et al. 2010. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 138: 905-912.
264. Nelson, J. E., R. Bhattacharya, K. D. Lindor, N. Chalasani, S. Raaka, E. J. Heathcote, E. Miskovsky, E. Shaffer, S. J. Rulyak, and K. V. Kowdley. 2007. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology. 46: 723-729.
265. Duseja, A., R. Das, M. Nanda, A. Das, G. Garewal, and Y. Chawla. 2005. Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J. Gastroenterol. 11: 393-395.
266. Lin, T. J., C. L. Lin, C. S. Wang, S. O. Liu, and L. Y. Liao. 2005. Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan. World J. Gastroenterol. 11: 3905-3908.
267. Licata, A., M. E. Nebbia, G. Cabibbo, G. L. Iacono, F. Barbaria, V. Brucato, N. Alessi, S. Porrovecchio, V. Di Marco, A. Craxi, et al. 2009. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J. Gastroenterol. 15: 2132-2138.
268. Bugianesi, E., P. Manzini, S. D'Antico, E. Vanni, F. Longo, N. Leone, P. Massarenti, A. Piga, G. Marchesini, and M. Rizzetto. 2004. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 39: 179-187. (Pubitemid 38461480)
269. Silverman, E. K., and R. A. Sandhaus. 2009. Clinical practice. Alpha1-antitrypsin deficiency. N. Engl. J. Med. 360: 2749-2757.
270. Valenti, L., P. Dongiovanni, A. Piperno, A. L. Fracanzani, M. Maggioni, R. Rametta, P. Loria, M. A. Casiraghi, E. Suigo, R. Ceriani, et al. 2006. Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology. 44: 857-864. (Pubitemid 46489549)
271. Regev, A., C. Guaqueta, E. G. Molina, A. Conrad, V. Mishra, M. L. Brantly, M. Torres, M. De Medina, A. G. Tzakis, and E. R. Schiff. 2006. Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large casecontrol study. J. Pediatr. Gastroenterol. Nutr. 43 ( Suppl 1 ): S30-S35.
272. Strassburg, C. P., S. Kalthoff, and U. Ehmer. 2008. Variability and function of family 1 uridine-5′-diphosphate glucuronosyltransferases (UGT1A). Crit. Rev. Clin. Lab. Sci. 45: 485-530.
273. Lin, Y. C., P. F. Chang, F. C. Hu, M. H. Chang, and Y. H. Ni. 2009. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics. 124: e1221-e1227.
274. Leslie, E. M., R. G. Deeley, and S. P. Cole. 2005. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204: 216-237.
275. Choi, J. H., B. M. Ahn, J. Yi, J. H. Lee, S. W. Nam, C. Y. Chon, K. H. Han, S. H. Ahn, I. J. Jang, J. Y. Cho, et al. 2007. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics. 17: 403-415.
276. Pizarro, M., N. Balasubramaniyan, N. Solis, A. Solar, I. Duarte, J. F. Miquel, F. J. Suchy, M. Trauner, L. Accatino, M. Ananthanarayanan, et al. 2004. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut. 53: 1837-1843. (Pubitemid 39556907)
277. Sookoian, S., G. Castano, T. F. Gianotti, C. Gemma, and C. J. Pirola. 2009. Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J. Nutr. Biochem. 20: 765-770.
278. Meier, Y., C. Pauli-Magnus, U. M. Zanger, K. Klein, E. Schaeffeler, A. K. Nussler, N. Nussler, M. Eichelbaum, P. J. Meier, and B. Stieger. 2006. Interindividual variability of canalicular ATPbinding- cassette (ABC)-transporter expression in human liver. Hepatology. 44: 62-74. (Pubitemid 44049139)
279. Nabeshima, Y., S. Tazuma, K. Kanno, H. Hyogo, M. Iwai, M. Horiuchi, and K. Chayama. 2006. Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. Biochem. Biophys. Res. Commun. 346: 658-664.
280. Hirose, A., M. Ono, T. Saibara, Y. Nozaki, K. Masuda, A. Yoshioka, M. Takahashi, N. Akisawa, S. Iwasaki, J. A. Oben, et al. 2007. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 45: 1375-1381. (Pubitemid 46918321)
281. Ibanez, P., N. Solis, M. Pizarro, G. Aguayo, I. Duarte, J. F. Miquel, L. Accatino, and M. Arrese. 2007. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 22: 846-851.
282. Yokohama, S., M. Yoneda, M. Haneda, S. Okamoto, M. Okada, K. Aso, T. Hasegawa, Y. Tokusashi, N. Miyokawa, and K. Nakamura. 2004. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 40: 1222-1225. (Pubitemid 39425579)
283. Bataller, R., P. Gines, J. M. Nicolas, M. N. Gorbig, E. Garcia- Ramallo, X. Gasull, J. Bosch, V. Arroyo, and J. Rodes. 2000. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 118: 1149-1156. (Pubitemid 30346992)
284. Yoshiji, H., S. Kuriyama, J. Yoshii, Y. Ikenaka, R. Noguchi, T. Nakatani, H. Tsujinoue, and H. Fukui. 2001. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 34: 745-750. (Pubitemid 32927999)
285. Sookoian, S., G. Castano, S. I. Garcia, P. Viudez, C. Gonzalez, and C. J. Pirola. 2005. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Am. J. Gastroenterol. 100: 636-642.
286. Yoneda, M., K. Hotta, Y. Nozaki, H. Endo, T. Uchiyama, H. Mawatari, H. Iida, S. Kato, K. Fujita, H. Takahashi, et al. 2009. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int. 29: 1078-1085.